Name: reprogramming primary amniotic fluid and membrane cells to pluripotency in xeno-free conditions
Uploaded: 2017-11-27T13:00:00
Description: Watch this Scientific Journal Video about Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions at JoVE.com

この作品は、チューリッヒ大学、チューリッヒ大学、奨学金 10.216 と 12.176、スイス社会循環器科、スイス科学の下、サイエックス NMSChの Forschungskredit フォンこの上海虹橋によって支えられました。財団助成金 [320030 122273] の下と [310030 143992]、第 7 フレームワーク プログラム、生活バルブ、グラント [242008]、オルガ Mayenfisch 財団、EMDO 財団、大学病院チューリッヒの創業助成金 2012 の下欧州委員会と内部は、ミッチェルのがん研究所の資金調達。

プロトコル人間研究倫理委員会の機関のガイドラインに従います。研究のため羊水を使用して患者の書面による同意が得られました。
このプロトコル制度動物ケアおよび使用委員会南アラバマ大学のポリシーに従います。
1. 分離とプライマリ羊膜由来間葉系幹細胞の培養
<ol><li>
羊水細胞へのめっき
	<ol>
<li>羊水羊水検査の過程で医師?...

<ol>
	<li>Takahashi, K., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+pluripotent+stem+cells+from+mouse+embryonic+and+adult+fibroblast+cultures+by+defined+factors.">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</a> Cell. 126 (4), 663-676 (2006).</li><li>Yu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induced+Pluripotent+Stem+Cell+Lines+Derived+from+Human+Somatic+Cells.">Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells.</a> Science. 318 (5858), 1917-1920 (2007).</li><li>Trounson, A., DeWitt, N. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Pluripotent+stem+cells+progressing+to+the+clinic.">Pluripotent stem cells progressing to the clinic.</a> Nat. Rev. Mol. Cell Biol. 17 (3), 194-200 (2016).</li><li>Schmidt, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prenatally+fabricated+autologous+human+living+heart+valves+based+on+amniotic+fluid+derived+progenitor+cells+as+single+cell+source.">Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source.</a> Circulation. 116 (11 Suppl), I64-I70 (2007).</li><li>Weber, B., Zeisberger, S. M., Hoerstrup, S. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prenatally+harvested+cells+for+cardiovascular+tissue+engineering:+Fabrication+of+autologous+implants+prior+to+birth.">Prenatally harvested cells for cardiovascular tissue engineering: Fabrication of autologous implants prior to birth.</a> Placenta. 32, S316-S319 (2011).</li><li>Weber, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prenatally+engineered+autologous+amniotic+fluid+stem+cell-based+heart+valves+in+the+fetal+circulation.">Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation.</a> Biomaterials. 33 (16), 4031-4043 (2012).</li><li>Kehl, D., Weber, B., Hoerstrup, S. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bioengineered+living+cardiac+and+venous+valve+replacements:+current+status+and+future+prospects.">Bioengineered living cardiac and venous valve replacements: current status and future prospects.</a> Cardiovasc. Pathol. 25 (4), 300-305 (2016).</li><li>Slamecka, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Non-integrating+episomal+plasmid-based+reprogramming+of+human+amniotic+fluid+stem+cells+into+induced+pluripotent+stem+cells+in+chemically+defined+conditions.">Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions.</a> Cell Cycle. 15 (2), 234-249 (2016).</li><li>Jiang, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+Transgene-Free+Amniotic-Fluid-Derived+Induced+Pluripotent+Stem+Cells+for+Autologous+Cell+Therapy.">Human Transgene-Free Amniotic-Fluid-Derived Induced Pluripotent Stem Cells for Autologous Cell Therapy.</a> Stem Cells Dev. 23 (21), 2613-2625 (2014).</li><li>Pipino, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Trisomy+21+mid-trimester+amniotic+fluid+induced+pluripotent+stem+cells+maintain+genetic+signatures+during+reprogramming:+implications+for+disease+modeling+and+cryobanking.">Trisomy 21 mid-trimester amniotic fluid induced pluripotent stem cells maintain genetic signatures during reprogramming: implications for disease modeling and cryobanking.</a> Cell. Reprogram. 16 (5), 331-344 (2014).</li><li>Cai, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+human+induced+pluripotent+stem+cells+from+umbilical+cord+matrix+and+amniotic+membrane+mesenchymal+cells.">Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells.</a> J Biol. Chem. 285 (15), 11227-11234 (2010).</li><li>Ge, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+Amniotic+Mesenchymal+Stem+Cell-Derived+Induced+Pluripotent+Stem+Cells+May+Generate+a+Universal+Source+of+Cardiac+Cells.">Human Amniotic Mesenchymal Stem Cell-Derived Induced Pluripotent Stem Cells May Generate a Universal Source of Cardiac Cells.</a> Stem Cells Dev. 21 (15), 2798-2808 (2012).</li><li>Drozd, A. M., Walczak, M. P., Piaskowski, S., Stoczynska-Fidelus, E., Rieske, P., Grzela, D. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+human+iPSCs+from+cells+of+fibroblastic+and+epithelial+origin+by+means+of+the+oriP/EBNA-1+episomal+reprogramming+system.">Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system.</a> Stem Cell Res. Ther. 6 (1), (2015).</li><li>Kang, N. -. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Potential+antitumor+therapeutic+strategies+of+human+amniotic+membrane+and+amniotic+fluid-derived+stem+cells.">Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells.</a> Cancer Gene Ther. 19 (8), 517-522 (2012).</li><li>Moschidou, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Valproic+Acid+Confers+Functional+Pluripotency+to+Human+Amniotic+Fluid+Stem+Cells+in+a+Transgene-free+Approach.">Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach.</a> Mol. Ther. 20 (10), 1953-1967 (2012).</li><li>Kim, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Epigenetic+memory+in+induced+pluripotent+stem+cells.">Epigenetic memory in induced pluripotent stem cells.</a> Nature. 467 (7313), 285-290 (2010).</li><li>Chen, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemically+defined+conditions+for+human+iPSC+derivation+and+culture.">Chemically defined conditions for human iPSC derivation and culture.</a> Nature Methods. 8 (5), 424-429 (2011).</li><li>Yu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+Induced+Pluripotent+Stem+Cells+Free+of+Vector+and+Transgene+Sequences.">Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences.</a> Science. 324 (5928), 797-801 (2009).</li><li>Mart&#237;, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characterization+of+pluripotent+stem+cells.">Characterization of pluripotent stem cells.</a> Nat. Protoc. 8 (2), 223-253 (2013).</li><li>Chan, E. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Live+cell+imaging+distinguishes+bona+fide+human+iPS+cells+from+partially+reprogrammed+cells.">Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells.</a> Nat. Biotechnol. 27 (11), 1033-1037 (2009).</li><li>Adewumi, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characterization+of+human+embryonic+stem+cell+lines+by+the+International+Stem+Cell+Initiative.">Characterization of human embryonic stem cell lines by the International Stem Cell Initiative.</a> Nat. Biotechnol. 25 (7), 803-816 (2007).</li><li>M&#252;ller, F. -. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+bioinformatic+assay+for+pluripotency+in+human+cells.">A bioinformatic assay for pluripotency in human cells.</a> Nature Methods. 8 (4), 315-317 (2011).</li><li>Cahan, P., Li, H., Morris, S. A., Lummertz da Rocha, E., Daley, G. Q., Collins, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CellNet:+Network+Biology+Applied+to+Stem+Cell+Engineering.">CellNet: Network Biology Applied to Stem Cell Engineering.</a> Cell. 158 (4), 903-915 (2014).</li><li>Schopperle, W. M., DeWolf, W. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+TRA-1-60+and+TRA-1-81+Human+Pluripotent+Stem+Cell+Markers+Are+Expressed+on+Podocalyxin+in+Embryonal+Carcinoma.">The TRA-1-60 and TRA-1-81 Human Pluripotent Stem Cell Markers Are Expressed on Podocalyxin in Embryonal Carcinoma.</a> STEM CELLS. 25 (3), 723-730 (2007).</li><li>Ohnishi, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Premature+Termination+of+Reprogramming+In+Vivo+Leads+to+Cancer+Development+through+Altered+Epigenetic+Regulation.">Premature Termination of Reprogramming In Vivo Leads to Cancer Development through Altered Epigenetic Regulation.</a> Cell. 156 (4), 663-677 (2014).</li><li>Schlaeger, T. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+comparison+of+non-integrating+reprogramming+methods.">A comparison of non-integrating reprogramming methods.</a> Nature Biotechnology. 33 (1), 58-63 (2014).</li><li>M&#252;ller, F. -. J., Goldmann, J., L&#246;ser, P., Loring, J. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+call+to+standardize+teratoma+assays+used+to+define+human+pluripotent+cell+lines.">A call to standardize teratoma assays used to define human pluripotent cell lines.</a> Cell Stem Cell. 6 (5), 412-414 (2010).</li><li>Beers, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Passaging+and+colony+expansion+of+human+pluripotent+stem+cells+by+enzyme-free+dissociation+in+chemically+defined+culture+conditions.">Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions.</a> Nat. Protoc. 7 (11), 2029-2040 (2012).</li></ol>

胎児幹細胞から iPSC 生成の最初のフェーズは、胎児の組織、彼らの文化、拡張、および episomal リプログラミング プラスミドの導入からソース セルの抽出を伴います。このフェーズの後に、最初の完全にプログラムし直された植民地を拡大することができます前に約 14-18 日間の培養期間が続きます。最終段階は、iPSC クローンの成熟です。羊膜幹細胞の最初の抽出は、羊膜の組合せ機械と酵?...

潜在的なセル置換療法、疾患と発達モデルと薬物毒性スクリーニング1,2,3の誘導多能性幹細胞 (iPSC) の技術をもたらします。細胞の注入により、補充療法が概念的には可能、体外 (心筋パッチ) などの組織移植を区別またはティッシュ エンジニア リングによる再生を誘導します。羊水 (AFSC) と膜幹細胞 (AMSC) いずれかこれらの介入のための細胞の優れた供給源は、直接4,5,6、7リプログラミングの開始セル人口多能性8,9,10、11,12。
初期のアプローチに使用される未定義の文化システムや9,10、11,12の構成要素を伴うゲノムの統合を必要とするメソッドをプログラムし直します。最近の研究より少なく定義された基底膜添付ファイル マトリックス (BMM) は、羊膜上皮細胞から iPSC を生成に使用されたにもかかわらず xeno 自由な媒体を採用しました。しかし、奇形腫形成アッセイは in vitro 及び分子データの富と共に研究に含まれません。新生児線維芽細胞13と比較して約 8 高いリプログラミング効率を持っている羊水上皮細胞が見つかりました。別の研究で、羊水から間葉系幹細胞は多く高効率12iPSC に再プログラムするも発見されました。
多能性幹細胞はすべての 3 胚葉組織代表に区別でき、このように広範な可能性があります。小児患者が恩恵を収穫、リプログラミングとその自家羊水幹細胞の組織工学胎児と羊膜幹細胞周産期。さらに、(成体幹細胞14,15より低い) 胎児の幹細胞の分化の低レベルは、iPSC16でソース セルからエピジェネティックなバイアスの観測の保持に対処に役立つ可能性が理論的に。
羊水をプログラムし直すためのプロトコルの紹介し、膜幹細胞の多能性を化学的に組換えビトロネクチン17 (VTN) episomal プラスミド18を使用して xeno E8 培を定義します。流体と膜羊膜の細胞リプログラミングのソースとしての主な利点は、利用前とこのアプローチは主に小児組織工学に研究の利益周産期そしてこうして。

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	
	<tbody>
		<tr >
			<td >Tumor Dissociation Kit, human</td>
			<td >Miltenyi Biotec</td>
			<td >130-095-929</td>
			<td >tissue dissociation system, reagent kit, includes tissue dissociation tubes and tissue dissociation enzymes</td>
		</tr>
		<tr >
			<td >gentleMACS Dissociator</td>
			<td >Miltenyi Biotec</td>
			<td >130-093-235</td>
			<td >tissue dissociation system, dissociator</td>
		</tr>
		<tr >
			<td >Thermo Scientific&#8482; Shandon&#8482; Disposable Scalpel No. 10, Sterile, Individually Wrapped, 5.75 (14.6cm)</td>
			<td >Thermo-Fisher</td>
			<td >3120032</td>
			<td ></td>
		</tr>
		<tr >
			<td >70 &#181;m cell strainers</td>
			<td >Corning</td>
			<td >10054-456</td>
			<td ></td>
		</tr>
		<tr >
			<td >RPMI 1640 medium</td>
			<td >Thermo-Fisher</td>
			<td >32404014&#160;</td>
			<td ></td>
		</tr>
		<tr >
			<td >rocking platform</td>
			<td >VWR</td>
			<td >40000-300</td>
			<td ></td>
		</tr>
		<tr >
			<td >50 ml centrifuge tubes</td>
			<td >Thermo-Fisher</td>
			<td >339652</td>
			<td ></td>
		</tr>
		<tr >
			<td >15 ml centrifuge tubes</td>
			<td >Thermo-Fisher</td>
			<td >339650</td>
			<td ></td>
		</tr>
		<tr >
			<td >EBM-2 basal medium</td>
			<td >Lonza</td>
			<td >CC-3156</td>
			<td >basal medium for AFMC medium</td>
		</tr>
		<tr >
			<td >FGF 2 Human (expressed in E. coli, non-glycosylated)</td>
			<td >Prospec Bio</td>
			<td >CYT-218</td>
			<td >bFGF, supplement for AFMC medium</td>
		</tr>
		<tr >
			<td >EGF Human, Pichia</td>
			<td >Prospec Bio</td>
			<td >CYT-332&#160;</td>
			<td >EGF, supplement for AFMC medium</td>
		</tr>
		<tr >
			<td >LR3 Insulin Like Growth Factor-1 Human Recombinant</td>
			<td >Prospec Bio</td>
			<td >CYT-022</td>
			<td >IGF, supplement for AFMC medium</td>
		</tr>
		<tr >
			<td >Fetal Bovine Serum, embryonic stem cell-qualified</td>
			<td >Thermo-Fisher</td>
			<td >10439024</td>
			<td >FBS</td>
		</tr>
		<tr >
			<td >Antibiotic-Antimycotic (100X)</td>
			<td >Thermo-Fisher</td>
			<td >15240062&#160;</td>
			<td >for primary AFSC/AMSC, for routine AFSC/AMSC it should not be necessary, do not use in medium for transfected cells!</td>
		</tr>
		<tr >
			<td >Accutase cell detachment solution</td>
			<td >StemCell Technologies</td>
			<td >07920</td>
			<td >cell detachment enzyme</td>
		</tr>
		<tr >
			<td >CryoStor&#8482; CS10</td>
			<td >StemCell Technologies</td>
			<td >07930</td>
			<td >complete freezing medium</td>
		</tr>
		<tr >
			<td >PBS, pH 7.4</td>
			<td >Thermo-Fisher Scientific</td>
			<td >10010023&#160;</td>
			<td ></td>
		</tr>
		<tr >
			<td >EndoFree Plasmid Maxi Kit (10)</td>
			<td >Qiagen</td>
			<td >12362</td>
			<td >for plasmid isolation</td>
		</tr>
		<tr >
			<td >pEP4 E02S EN2K</td>
			<td >Addgene</td>
			<td >20925</td>
			<td >EN2K, reprogramming factors Oct4+Sox2, Nanog+Klf4</td>
		</tr>
		<tr >
			<td >pEP4 E02S ET2K</td>
			<td >Addgene</td>
			<td >20927</td>
			<td >ET2K, reprogramming factors Oct4+Sox2, SV40LT+Klf4</td>
		</tr>
		<tr >
			<td >pCEP4-M2L</td>
			<td >Addgene</td>
			<td >20926</td>
			<td >M2L, reprogramming factors c-Myc+LIN28</td>
		</tr>
		<tr >
			<td >NanoDrop 2000c UV-Vis Spectrophotometer</td>
			<td >Thermo-Fisher</td>
			<td >ND-2000C</td>
			<td >spectrophotometer</td>
		</tr>
		<tr >
			<td >Neon&#174; Transfection System</td>
			<td >Thermo-Fisher</td>
			<td >MPK5000</td>
			<td >transfection system, components: 
			Neon pipette - transfection pipette 
			Neon device - transfection device</td>
		</tr>
		<tr >
			<td >Neon&#174; Transfection System 10 &#181;L Kit</td>
			<td >Thermo-Fisher</td>
			<td >MPK1025</td>
			<td >consumables kit for the Neon Transfection System, it contains: 
			Neon tip - transfection tip 
			Neon tube - transfection tube 
			buffer R - resuspension buffer 
			buffer E - electrolytic buffer</td>
		</tr>
		<tr >
			<td >Stemolecule&#8482; Sodium Butyrate</td>
			<td >StemGent</td>
			<td >04-0005</td>
			<td >small molecule enhancer of reprogramming</td>
		</tr>
		<tr >
			<td >TeSR-E8</td>
			<td >StemCell Technologies</td>
			<td >05940</td>
			<td >E8 medium</td>
		</tr>
		<tr >
			<td >Vitronectin XF&#8482;</td>
			<td >StemCell Technologies</td>
			<td >07180</td>
			<td >VTN, stock concentration 250 &#181;g/ml, used for coating at 1 &#181;g/cm2 in vitronectin dilution (CellAdhere) buffer</td>
		</tr>
		<tr >
			<td >CellAdhere&#8482; Dilution Buffer</td>
			<td >StemCell Technologies</td>
			<td >07183</td>
			<td >vitronectin dilution buffer</td>
		</tr>
		<tr >
			<td >UltraPure&#8482; 0.5M EDTA, pH 8.0</td>
			<td >Thermo-Fisher</td>
			<td >15575020</td>
			<td >dilute with PBS to 0.5 mM before use</td>
		</tr>
		<tr >
			<td >EVOS&#174; FL Imaging System</td>
			<td >Thermo-Fisher Scientific</td>
			<td >AMF4300</td>
			<td >LCD imaging microscope system</td>
		</tr>
		<tr >
			<td >CKX53 Inverted Microscope</td>
			<td >Olympus</td>
			<td ></td>
			<td >phase contrast cell culture microscope</td>
		</tr>
		<tr >
			<td >Pierce&#8482; 16% Formaldehyde (w/v), Methanol-free</td>
			<td >Thermo-Fisher</td>
			<td >28908</td>
			<td >dilute to 4% with PBS before use, diluted can be stored at 2-8 &#176;C for 1 week</td>
		</tr>
		<tr >
			<td >Perm Buffer III</td>
			<td >BD Biosciences</td>
			<td >558050</td>
			<td >permeabilization buffer, chill to -20 &#176;C before use</td>
		</tr>
		<tr >
			<td >Mouse IgG1, &#954; Isotype Control, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >557782</td>
			<td >isotype control for Oct3/4A, Nanog</td>
		</tr>
		<tr >
			<td >Mouse IgG1, &#954; Isotype Control, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >557783</td>
			<td >isotype control for Sox2</td>
		</tr>
		<tr >
			<td >Mouse anti-human Oct3/4 (Human Isoform A), Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >561628</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse anti-human Nanog, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >560791</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse anti-human Sox-2, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >562139</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse IgGM, &#954; Isotype Control, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >401617</td>
			<td >isotype control for TRA-1-60</td>
		</tr>
		<tr >
			<td >Mouse IgGM, &#954; Isotype Control, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >401618</td>
			<td >isotype control for TRA-1-81</td>
		</tr>
		<tr >
			<td >Mouse anti-human TRA-1-60, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >330613</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse anti-human TRA-1-81, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >330705</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse IgG1, &#954; Isotype Control, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >400129</td>
			<td >isotype control for SSEA-1</td>
		</tr>
		<tr >
			<td >Mouse IgG3, &#954; Isotype Control, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >401321</td>
			<td >isotype control for SSEA-4</td>
		</tr>
		<tr >
			<td >Mouse anti-human SSEA-1, Alexa Fluor&#174; 488</td>
			<td >BD Biosciences</td>
			<td >323010</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mouse anti-human SSEA-4, Alexa Fluor&#174; 647</td>
			<td >BD Biosciences</td>
			<td >330407</td>
			<td ></td>
		</tr>
		<tr >
			<td >Affinipure F(ab&#39;)2 Fragment Goat Anti-Mouse IgG+IgM, Alexa Fluor&#174; 488</td>
			<td >Jackson Immunoresearch</td>
			<td >115-606-068</td>
			<td >use at a dilution of 1:600 or further optimize</td>
		</tr>
		<tr >
			<td >Affinipure F(ab&#39;)2 Fragment Goat Anti-Mouse IgG+IgM, Alexa Fluor&#174; 647</td>
			<td >Jackson Immunoresearch</td>
			<td >115-546-068</td>
			<td >use at a dilution of 1:600 or further optimize</td>
		</tr>
		<tr >
			<td >DAPI</td>
			<td >Thermo-Fisher Scientific</td>
			<td >D21490</td>
			<td >stock solution 10 mM, further dilute to 1:12.000 for a working solution</td>
		</tr>
		<tr >
			<td >Corning&#174; Matrigel&#174; Growth Factor Reduced, Phenol Red-Free</td>
			<td >Corning</td>
			<td >356231</td>
			<td >basement membrane matrix (BMM)</td>
		</tr>
		<tr >
			<td >scid-beige mice, female</td>
			<td >Taconic</td>
			<td >CBSCBG-F</td>
			<td ></td>
		</tr>
		<tr >
			<td >RNeasy Plus Mini Kit (50)</td>
			<td >Qiagen</td>
			<td >74134</td>
			<td >RNA isolation kit</td>
		</tr>
		<tr >
			<td >T-25 flasks, tissue culture-treated</td>
			<td >Thermo-Fisher</td>
			<td >156367</td>
			<td ></td>
		</tr>
		<tr >
			<td >T-75 flasks, tissue culture-treated</td>
			<td >Thermo-Fisher</td>
			<td >156499</td>
			<td ></td>
		</tr>
		<tr >
			<td >Nunc&#8482; tissue-culture dish</td>
			<td >Thermo-Fisher</td>
			<td >12-567-650&#160;</td>
			<td >10 cm tissue culture dish</td>
		</tr>
		<tr >
			<td >6-well plates, tissue-culture treated</td>
			<td >Thermo-Fisher</td>
			<td >140675</td>
			<td ></td>
		</tr>
		<tr >
			<td >Neubauer counting chamber (hemacytometer)</td>
			<td >VWR</td>
			<td >15170-173</td>
			<td ></td>
		</tr>
		<tr >
			<td >Mr. Frosty&#8482; Freezing Container</td>
			<td >Thermo-Fisher</td>
			<td >5100-0001&#160;</td>
			<td >freezing container</td>
		</tr>
		<tr >
			<td >FACS tubes, Round Bottom Polystyrene Test Tube, 5ml</td>
			<td >Corning</td>
			<td >352058</td>
			<td >5 ml polystyrene tubes</td>
		</tr>
		<tr >
			<td >Eppendorf tubes, 1.5 ml</td>
			<td >Thermo-Fisher</td>
			<td >05-402-96</td>
			<td >1.5 ml microcentrifuge tubes</td>
		</tr>
		<tr >
			<td >PCR tubes, 200 &#181;l</td>
			<td >Thermo-Fisher</td>
			<td >14-222-262</td>
			<td ></td>
		</tr>
		<tr >
			<td >pipette tips, 100 to 1250 &#181;l</td>
			<td >Thermo-Fisher</td>
			<td >02-707-407</td>
			<td >narrow-bore 1 mL tips</td>
		</tr>
		<tr >
			<td >pipette tips, 5 to 300 &#181;l</td>
			<td >Thermo-Fisher</td>
			<td >02-707-410</td>
			<td ></td>
		</tr>
		<tr >
			<td >pipette tips, 0.1 to 10 &#181;l</td>
			<td >Thermo-Fisher</td>
			<td >02-707-437</td>
			<td ></td>
		</tr>
		<tr >
			<td >wide-bore pipette tips, 1000 &#181;l</td>
			<td >VWR</td>
			<td >89049-166</td>
			<td >wide-bore 1 mL tips</td>
		</tr>
		<tr >
			<td >glass Pasteur pipettes</td>
			<td >Thermo-Fisher</td>
			<td >13-678-20A</td>
			<td ></td>
		</tr>
		<tr >
			<td >ethanol, 200 proof</td>
			<td >Thermo-Fisher</td>
			<td >04-355-451</td>
			<td ></td>
		</tr>
		<tr >
			<td >vortex mixer</td>
			<td >VWR</td>
			<td >10153-842</td>
			<td ></td>
		</tr>
		<tr >
			<td >chambered coverglass, 8-well, 1.5mm borosilicate glass</td>
			<td >Thermo-Fisher</td>
			<td >155409</td>
			<td >glass-bottom confocal-grade cultureware</td>
		</tr>
		<tr >
			<td >22G needles</td>
			<td >VWR</td>
			<td >82002-366</td>
			<td ></td>
		</tr>
		<tr >
			<td >insulin syringes</td>
			<td >Thermo-Fisher</td>
			<td >22-253-260</td>
			<td ></td>
		</tr>
		<tr >
			<td >Formalin solution, neutral buffered, 10%</td>
			<td >Sigma-Aldrich</td>
			<td >HT501128-4L</td>
			<td >fixation of explanted teratomas</td>
		</tr>
		<tr >
			<td >Illumina HT-12 v4 Expression BeachChip</td>
			<td >Illumina</td>
			<td >BD-103-0204</td>
			<td >expression microarray, supported by PluriTest, discontinued by manufacturer</td>
		</tr>
		<tr >
			<td >PrimeView Human Genome U219 Array Plate</td>
			<td >Thermo-Fisher</td>
			<td >901605</td>
			<td >expression microarray (formerly Affymetrix brand), soon to be supported by PluriTest</td>
		</tr>
		<tr >
			<td >GeneChip&#8482; Human Genome U133 Plus 2.0 Array</td>
			<td >Thermo-Fisher</td>
			<td >902482</td>
			<td >expression microarray (formerly Affymetrix brand), supported by CellNet, soon to be supported by PluriTest</td>
		</tr>
		<tr >
			<td >PluriTest&#174;</td>
			<td >Coriell Institute</td>
			<td ></td>
			<td >www.pluritest.org, free service for bioinformatic assessment of pluripotency, accepts microarray data - *.idat files from HT-12 v4 platform, soon to support U133, U219 microarray and RNA sequencing data</td>
		</tr>
		<tr >
			<td >CellNet</td>
			<td >Johns Hopkins University</td>
			<td ></td>
			<td >cellnet.hms.harvard.edu, free service for bioinformatic identification of cell type, including plutipotent stem cells, based on U133 microarray data - *.cel files, soon to support RNA sequencing data</td>
		</tr>
	</tbody>
</table>

reprogramming primary amniotic fluid and membrane cells to pluripotency in xeno-free conditions

自家細胞を用いた治療法は、誘導多能性幹細胞の導入により現実に近い方のステップを得た。羊水など膜幹細胞、胎児の幹細胞は、組織工学、将来小児の介入と幹細胞のバンキングの iPSC にプログラムし直す約束の未分化細胞のユニークな型を表します。ここで提示されたプロトコルを抽出するための最適化手順をについて説明し、プライマリ羊水液と膜間葉系幹細胞を培養させ、episomal 誘導これら完全に化学的に定義された培養細胞からの多能性幹細胞人間の組換えビトロネクチンおよび E8 媒体利用の条件。-フローサイトメトリー、共焦点レーザー顕微鏡、奇形腫形成と転写プロファイリング-厳格な方法を適用することによって新しい行の評価についても述べる.新しく生成された行は、SSEA 1 のマーカーが陰性でありながら胚性幹細胞-Oct3/4 a、Nanog、Sox2、トラ-1-60、トラ-1-81-SSEA 4 のマーカーを表現します。幹細胞は、6-8 週間でベージュ scid マウスにおける奇形を形成し、奇形を含むすべての 3 つの細菌層の代表的な組織。Bioinformatic 多能性評価アルゴリズムをグローバル発現マイクロ アレイ データを提出することにより、行の転写プロファイリングすべて行多能性としたがって、このアプローチは、動物実験に代わる。IPSC の新しい行は、分化とティッシュ エンジニア リングの最適化を含む下流の実験で容易に使用できます。

通知の書面による同意は、遺伝テストの目的と研究のための流体の小さい因数を捧げての羊水を採取する前に患者から得られました。胎盤は医療廃棄物を表し、同意は羊膜の研究の使用のため必要ありません。羊水の流体と膜幹細胞は典型的な間葉系プロパティを表示、形態学的、細胞は紡錘形と相明るい。リプログラミング、セル間葉系上皮性 (MET) 遷移に入るし、...

Watch this Scientific Journal Video about Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions at JoVE.com

Reprogramming Primary Amniotic Fluid and Membrane Cells to Pluripotency in Xeno-free Conditions

このプロトコルでは、完全に化学的に定義された条件における非統合 episomal アプローチを用いた誘導多能性幹細胞にプライマリ羊水液と膜間葉系幹細胞のリプログラミングをについて説明します。抽出、文化、リプログラミング、および厳格な方法で結果の誘導多能性幹細胞の特性の手順に。

主な羊水および膜 Xeno 無料条件で多能性細胞をリプログラミング

Autologous cell-based therapies got a step closer to reality with the introduction of induced pluripotent stem cells. Fetal stem cells, such as amniotic ...

Research

JoVE Journal

Developmental Biology

Stable and Efficient Genetic Modification of Cells in the Adult Mouse V-SVZ for the Analysis of Neural Stem Cell Autonomous and Non-autonomous Effects

神経の分析のための成体マウスのV-SVZにおける細胞の安定的かつ効率的な遺伝子改変幹細胞自律と非自律効果

Relatively quiescent somatic stem cells support life-long cell renewal in most adult tissues. Neural stem cells in the adult mammalian brain are ...

The Production of Pluripotent Stem Cells from Mouse Amniotic Fluid Cells Using a Transposon System

トランスポゾンのシステムを用いたマウスの羊水細胞から多能性幹細胞の作製

Induced pluripotent stem (iPS) cells are generated from mouse and human somatic cells by forced expression of defined transcription factors using ...

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell MSC Spheroids Primed in 3-D Cultures Under Xeno-free Conditions

異種非含有条件下での3次元培養における治療間葉系幹/間質細胞の生産と管理（MSC）スフェロイドプライム

Mesenchymal stem/stromal cells (MSCs) hold great promise in bioengineering and regenerative medicine. MSCs can be isolated from multiple adult tissues via ...

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

ティッシュ・エンジニアリングと疾病調査に使用するための小児のヒト食道上皮細胞の条件付き再プログラミング

Identifying and expanding patient-specific cells in culture for use in tissue engineering and disease investigation can be very challenging. Utilizing ...

Computational Analysis of the Caenorhabditis elegans Germline to Study the Distribution of Nuclei, Proteins, and the Cytoskeleton

Computational Analysis of the Caenorhabditis elegans Germline to Study the Distribution of Nuclei, Proteins, and the Cytoskeleton

核の分布、蛋白質および細胞骨格を研究する線虫生殖細胞の解析

The Caenorhabditis elegans (C. elegans) germline is used to study several biologically important processes including stem cell development, apoptosis, and ...

Induction and Validation of Cellular Senescence in Primary Human Cells

ひと初代細胞における細胞老化の誘導性

Cellular senescence is a state of permanent cell cycle arrest activated in response to different damaging stimuli. Activation of cellular senescence is a ...

Defined Xeno-free and Feeder-free Culture Conditions for the Generation of Human iPSC-derived Retinal Cell Models

Xeno 無料の定義された、人間の世代の iPSC 由来網膜細胞モデル フィーダー フリー培養条件

The production of specialized cells from pluripotent stem cells provides a powerful tool to develop new approaches for regenerative medicine. The use of ...

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model

マウス モデルにおける静脈内投与と胎嚢内子宮内移植

In utero transplantation (IUT) is a unique and versatile mode of therapy that can be used to introduce stem cells, viral vectors, or any other substances ...

Induction of Endothelial Differentiation in Cardiac Progenitor Cells Under Low Serum Conditions

低血清条件下で心臓前駆細胞の内皮への分化の誘導

Cardiac progenitor cells (CPCs) may have therapeutic potential for cardiac regeneration after injury. In the adult mammalian heart, intrinsic CPCs are ...

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

リネージュの赤芽球系前駆細胞に成体マウス線維芽細胞のリプログラミングを直接します。

Erythroid cell commitment and differentiation proceed through activation of a lineage-restricted transcriptional network orchestrated by a group of cell ...